SLC5A2 and myocardial infarction: Indeed, adequate control of DM through sodium-glucose cotransporter-2 inhibitor (21) or glucagon-like peptide-1 receptor agonists (22) are known to reduce the risk of ischemic stroke or cardiovascular death as well as recurrent myocardial infarction, implying that systemic treatment (drugs) rather than local treatment (PCI) is essential for management of diabetic patients with cardiovascular complications.